Recent performance snapshot

DaVita (DVA) has drawn fresh attention after a strong run in its stock price, with the shares last closing at $195.03. The move comes alongside solidly positive returns across multiple recent time frames.

The recent 3.8% 1 day share price return builds on stronger momentum, with a 26.6% 1 month share price return and a 70.3% year to date share price return, alongside a 42.6% 1 year total shareholder return. This suggests sentiment around DaVita has shifted meaningfully in recent months.

If DaVita's move has you looking across healthcare, this could be a good moment to scan other opportunities in data driven medical care and treatment using our 39 healthcare AI stocks

With DaVita trading around $195 and sitting close to its average analyst price target, plus modelled intrinsic value suggesting a premium, the key question is whether there is still a buying opportunity here or if markets are already pricing in future growth.

Most Popular Narrative: 1% Overvalued

With DaVita last closing at $195.03 against a narrative fair value of $193.71, the current set up hinges on how earnings power and margins evolve from here.

Ongoing investments in technology, AI, and data analytics are driving structural cost reductions through improved operational efficiency and enhanced clinical outcomes, which management expects to support margin improvement even in periods of flat or negative volume growth. The company's disciplined cost management and improved labor productivity have led to lower patient care costs per treatment, and with higher employee retention and training efficiencies expected to continue, this trend provides ongoing tailwinds for net margins.

Curious what kind of revenue path, margin lift and future earnings multiple are baked into that fair value, and how much share shrink matters to the end result.

Result: Fair Value of $193.71 (OVERVALUED)

However, there are still key risks to watch, including pressure from reimbursement rates that lag costs and operational issues that could keep treatment volumes under strain.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another view on DaVita's valuation

The narrative fair value of $193.71 suggests DaVita is about 1% overvalued at $195.03, but the current P/E of 16.6x tells a slightly different story. That multiple sits below the US market at 18.9x, the US Healthcare industry at 22.9x, and the estimated fair ratio of 24.3x. This points to a lower valuation risk than the DCF based view alone might imply.

For investors, that gap between a seemingly full price on cash flow models and a lower than peer P/E raises a simple question: which signal should carry more weight when you think about what you are willing to pay for DaVita?

Next Steps

With sentiment mixed between opportunity and risk, this is a good time to move quickly. Review the numbers for yourself and decide where you stand by weighing the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If DaVita is on your radar, do not stop here. Use this momentum to hunt for other stocks that fit your style before the crowd catches on.

• Target stability by reviewing companies screened for resilient balance sheets and steady fundamentals through the solid balance sheet and fundamentals stocks screener (47 results).
• Chase value by scanning for quality stocks that trade below their estimated worth using the 46 high quality undervalued stocks.
• Spot early opportunities by searching for financially solid smaller stocks highlighted in the 24 elite penny stocks with strong financials.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.